[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @jy201506 Jinzhou Yuan Jinzhou Yuan posts on X about $iova, waterfall, combo the most. They currently have XX followers and X posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::3347605366/interactions)  ### Mentions: X [#](/creator/twitter::3347605366/posts_active)  ### Followers: XX [#](/creator/twitter::3347605366/followers)  ### CreatorRank: XXXXXXXXX [#](/creator/twitter::3347605366/influencer_rank)  ### Social Influence [#](/creator/twitter::3347605366/influence) --- **Social topic influence** [$iova](/topic/$iova) #14, [waterfall](/topic/waterfall), [combo](/topic/combo) **Top assets mentioned** [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) ### Top Social Posts [#](/creator/twitter::3347605366/posts) --- Top posts by engagements in the last XX hours "@kainvests in PDL11% similar ORR(55%) with Amtagvi (IOV-COM-202 3A (SITC 2024)). However two key diff: 1) $IOVA study pts received X (04) pLOT compared to the strict X pLOT population here; 2) the response here isn't as deep based on the waterfall plot and no CR here.Durability is key" [X Link](https://x.com/jy201506/status/1979756802419077276) [@jy201506](/creator/x/jy201506) 2025-10-19T03:49Z XX followers, XXX engagements "@kainvests Thanks for sharing the data. keep the $IOVA community alerted about new developments" [X Link](https://x.com/jy201506/status/1979760702379405655) [@jy201506](/creator/x/jy201506) 2025-10-19T04:05Z XX followers, XXX engagements "@n_hatami @kainvests in 1L the lag3 combo is already in phase X. with their poor efficacy data in 2L they gave up in 2L and hoping to gain some incremental enhancement by combo with SOC. $IOVA is chasing in 2L backed by early encouraging efficacy data. there's literally no direct competition there" [X Link](https://x.com/jy201506/status/1980009074046513533) [@jy201506](/creator/x/jy201506) 2025-10-19T20:32Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@jy201506 Jinzhou Yuan
Jinzhou Yuan posts on X about $iova, waterfall, combo the most. They currently have XX followers and X posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
Mentions: X #
Followers: XX #
CreatorRank: XXXXXXXXX #
Social Influence #
Social topic influence $iova #14, waterfall, combo
Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA)
Top Social Posts #
Top posts by engagements in the last XX hours
"@kainvests in PDL11% similar ORR(55%) with Amtagvi (IOV-COM-202 3A (SITC 2024)). However two key diff: 1) $IOVA study pts received X (04) pLOT compared to the strict X pLOT population here; 2) the response here isn't as deep based on the waterfall plot and no CR here.Durability is key"
X Link @jy201506 2025-10-19T03:49Z XX followers, XXX engagements
"@kainvests Thanks for sharing the data. keep the $IOVA community alerted about new developments"
X Link @jy201506 2025-10-19T04:05Z XX followers, XXX engagements
"@n_hatami @kainvests in 1L the lag3 combo is already in phase X. with their poor efficacy data in 2L they gave up in 2L and hoping to gain some incremental enhancement by combo with SOC. $IOVA is chasing in 2L backed by early encouraging efficacy data. there's literally no direct competition there"
X Link @jy201506 2025-10-19T20:32Z XX followers, XXX engagements